retatrutide mechanism glp-1 gip glucagon triple agonist Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature The Effects of Dual GLP-1/GIP
Description
The higher tirzepatide doses of 10 and 15 mg were noninferior compared to insulin glargine for the change in HbA1c (primary endpoint)
N Engl J Med 387 , 205216 (2022)
Reviews and primary research increasingly examine why dual and triple approaches outperform GLP-1 alone, exploring the synergistic effects of GIP co-agonism and glucagon receptor activation on both weight loss and metabolic parameters [1, 2, 3, 4]
This means widespread access might not come until 2027-2028 or later
doi: 10.1111/jdi.12450 [DOI] [PMC free article] [PubMed] [Google Scholar] 59.Weaver RE, Donnelly D, Wabitsch M, Grant PJ, Balmforth AJ
